Published online Oct 21, 2020. doi: 10.3748/wjg.v26.i39.5944
Peer-review started: June 28, 2020
First decision: July 28, 2020
Revised: August 8, 2020
Accepted: September 25, 2020
Article in press: September 25, 2020
Published online: October 21, 2020
Processing time: 114 Days and 22.8 Hours
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD), ulcerative colitis and unclassified entities. CD commonly involves the terminal ileum and colon but at the time of diagnosis it can be confined to the small bowel (SB) in about 30% of the patients, especially in the young ones. Management of isolated SB-CD can be challenging and objective evaluation of the SB mucosa is essential in differentiating CD from other enteropathies to achieve therapeutic decisions and to plan the follow-up. The introduction of cross-sectional imaging techniques and capsule endoscopy (CE) have significantly expanded the ability to diagnose SB diseases providing a non-invasive test for the visualization of the entire SB mucosa. The main CE limitations are the low specificity, the lack of therapeutic capabilities and the impossibility to take biopsies. Device assisted enteroscopy (DAE) enables histological confirmation when traditional endoscopy, capsule endoscopy and cross-sectional imaging are inconclusive and also allows therapeutic interventions such as balloon stricture dilation, intralesional steroid injection, capsule retrieval and more recently stent insertion. In the current review we will discuss technical aspect, indications and safety profile of DAE in children and adults with IBD.
Core Tip: Evaluation of the small bowel (SB) mucosa is essential in differentiating Crohn’s disease (CD) from other enteropathies to achieve therapeutic decisions and to plan follow-up. The introduction of cross-sectional imaging techniques and capsule endoscopy have significantly improved the diagnostic approach to SB disease providing a non-invasive diagnostic method for the visualization of the entire SB mucosa. However, Device assisted enteroscopy (DAE) has further revolutionized management of SB-CD enabling histological confirmation and allowing therapeutic interventions. In the current review we will discuss technical aspect, indications and safety profile of DAE in children and adults with inflammatory bowel disease.